title: Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment.
authors.forename: M
authors.initials: M
authors.lastname: Breccia
authors.forename: M
authors.initials: M
authors.lastname: Muscaritoli
authors.forename: Z
authors.initials: Z
authors.lastname: Aversa
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
authors.forename: G
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D001786:Blood Glucose / Q000187:drug effects*; D015897:Comorbidity; D003920:Diabetes Mellitus; D005260:Female; D005947:Glucose / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D007333:Insulin Resistance; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D001786:Blood Glucose; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D005947:Glucose